Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: A systematic review and meta-analysis

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Veale, David ^a,d   Miles, Sarah ^a   Smallcombe, Nicola ^b   Ghezai, Haben ^a   Goldacre, Ben ^c   Hodsoll, John ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti psychotic; Obsessive compulsive disorder; Selective serotonergic reuptake inhibitor

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOMIPRAMINE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW; TIC; TREATMENT DURATION; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE; ADULT; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG RESISTANCE; OBSESSIVE-COMPULSIVE DISORDER; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BENZODIAZEPINES; CLOMIPRAMINE; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; QUETIAPINE FUMARATE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84924057919     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0317-5     Document Type: Article

References (38)

1. National Collaborating Centre for Mental Health (NCCMH): Obsessive compulsive disorder: core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. London: Gaskell and BPS; 2006.
2. Phillips KA: Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatr 2005, 162(2):377-379.
3. National Institute for Health & Clinical Excellence (NICE): Obsessive compulsive disorder: evidence update September 2013. National Institute for Health & Clinical Excellence; 2013.
4. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S: Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev 2010, 12:1-44.
5. Fineberg NA, Reghunandanan S, Brown A, Pampaloni I: Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry 2013, 47(2):121-141.
6. Stein DJ, Koen N, Fineberg N, Fontenelle LF, Matsunaga H, Osser D, Simpson HB: A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep 2012, 14(3):211-219.
7. Goldacre B: Bad pharma: how drug companies mislead doctors and harm patients. Random House Digital, Inc; 2013.
8. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269.
9. McDougle CJ, Goodman WK, Leckman JF: Haloperidol addition in fluvoxamine refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994, 51:302-308.
10. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MK, Lassig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382(9896):951-962.
11. Goodman WK, Price LH, Rasmussen SA, Mazure C: The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
12. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000, 57(8):794-801.
13. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK: A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004, 55(5):553-555.
14. Hollander E, Rossi NB, Sood E, Pallanti S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003, 6(4):397-401.
15. Erzegovesi SGE, Siliprandi F, Bellodi L: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005, 15(1):69-74.
16. Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT: Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry 2013, 70(11):1190-1199.
17. Storch E, Goddard A, Grant J, De Nadai A, Goodman W, Mutch P, Medlock C, Odlaug B, McDougle C, Murphy T: Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry 2013, 74(6):e527-e532.
18. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004, 65(4):565-568.
19. Denys D, de Geus F, van Megen HJ, Westenberg HG: A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004, 65(8):1040-1048.
20. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry 2005, 5:5-13.
21. Fineberg NA, Sivakumaran T, Roberts A, Gale T: Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005, 20(4):223-226.
22. Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F: Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2008, 28(5):550-554.
23. Diniz JB, Shavitt RG, Fossaluza V, Koran L, de Bragança Pereira CA, Miguel EC: A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 2011, 31(6):763-768.
24. Muscatello MR, Bruno A, Pandolfo G, Mico U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA: Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2011, 31(2):174-179.
25. Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A: Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety 2012, 29(10):850-854.
26. Oxman AD, Group GW: Grading quality of evidence and strength of recommendations. BMJ 2004, 328(19):1490-1494.
27. Bradburn MJ, Deeks JJ, Altman DG: Metan-an alternative meta-analysis command. Stata Tech Bull 1987, 8(44):4-15.
28. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J: Metan: fixed-and random-effects meta-analysis. Stata J 2008, 8(1):3-28.
29. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
30. Rosenthal R: Meta-Analytic Procedures for Social Research. London: Sage Publications Inc. 1991.
31. Tatari F, Khazaei H, Jahandar F, Rezaei M: Effect of adding risperidone to fluoxetine in treatment of obsession compulsion disorder patients. Life Sci J 2013, 10(11s):153-157.
32. Streiner D, Geddes J: Intention to treat analysis in clinical trials when there are missing data. Evid Based Ment Health 2001, 4(3):70-71.
33. Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ: A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009, 70(6):863-868.
34. Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, Alsobrook J, Peterson BS, Cohen DJ, Rasmussen SA: Symptoms of obsessive-compulsive disorder. Am J Psychiatr 1997, 154(7):911-917.
35. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J: Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002, 5(02):181-191.
36. Jacobson NS, Truax P: Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991, 59(1):12-19.
37. Pallanti S, Quercioli L, Paiva R, Koran L: Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 1999, 14(2):101-106.
38. Pampaloni I, Sivakumaran T, Hawley CJ, Al Allaq A, Farrow J, Nelson S, Fineberg NA: High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. J Psychopharmacol 2010, 24:1439-1445.